Company Profile

Acenta Discovery Inc
Profile last edited on: 5/28/21      CAGE: 3PKK2      UEI:

Business Identifier: Chemistry based drug discovery product
Year Founded
2002
First Award
2003
Latest Award
2006
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9030 South Rita Road Suite 300
Tucson, AZ 85717
   (520) 799-7304
   info@acentadiscovery.com
   www.acentadiscovery.com
Location: Single
Congr. District: 02
County: 

Public Profile

Acenta Discovery provides chemistry based drug discovery products and services for large pharmaceutical and research firms, as well as small and middle-market biotechnology firms. Since being founded in November 2002 by an accomplished scientist with two drugs currently in the clinic who was trained at Harvard under Dr. Elias J. Corey (Nobel Prize and Priestley Medal Recipient) in partnership with an experienced executive and entrepreneur who led a division of a multi-national chemical company acquired by Zeneca, Acenta has shown a steady rate of growth in new client contracts, profitability and innovations through its on-going research supported by federal grant funding. Acenta produces value for partners by providing them cutting edge medicinal chemistry solutions on a fee-for-service basis, as well as access to the firm's growing pipeline of intellectual property in the fields of cancer and neurosciences. The company offers both service and product solutions including Quick-HitTM compound libraries to initiate client and partner research programs, focused chemistry services (computational chemistry, synthetic chemistry, chemistry consulting), and composition of matter that may be accessed through licensing or strategic development

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 2 NIH $749,986
Project Title: Development of NET-Selective Piperidine-Based PET Ligand
2005 2 NIH $596,620
Project Title: Akt Inhibitors to Treat Ewing's Sarcoma
2005 2 NIH $348,523
Project Title: Caspase Inhibitor for Neuroprotection
2004 2 NIH $545,039
Project Title: NET - Selective Ligands for the Treatment of Depression

Key People / Management

  Hans Roth -- President

  Annaliisa Brownell

  Kenneth M Johnson

  Alan P Kozikowski -- Chairman and Founder

  Francis J Maloney -- Chief Business Officer

  Jeffrey A Toretsky

  Alexander G Yakovlev

  Jia Zhou

Company News

There are no news available.